Date and Time: Tuesday 14th & Wednesday 15th January 2014, 1000 - 1600

Minutes: Final

Guideline Development Group Meeting
Place: National Clinical Guideline Centre, 180 Great Portland Street, London W1W 5QZ

Present: Stephanie Amiel (Chair)
Gus Brooks (present for items 1 – 8)
Arthur Durrant
Emily Davies
Elisabetta Fenu
Michael Flynn
Roger Gadsby
Peter Hammond
Bernard Higgins
Mike Kendall
Chris Kiff
Rayaz Malik (invited expert)
Vibhuti Mistry
Henrietta Mulnier
Rachel O’Mahony
Nancy Pursey
Vicky Ruszala (present for item 5 onwards)
Perdy van den Berg

In attendance:

<table>
<thead>
<tr>
<th>NICE Staff:</th>
<th>Claire Ruiz</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invited expert:</td>
<td>Rayaz Malik</td>
</tr>
</tbody>
</table>

Observers:

| Anita Phung |

Notes

1. The chair welcomed the group to the twelfth and thirteenth meeting of this GDG. Apologies were received from Stuart Smellie. The Chair asked all GDG members to declare any new conflicts of interest and none were declared. The chair specified the conflicts relevant to topics to be covered at this meeting. All GDG members were asked and declared that they knew of no active personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in relation to these topics.
Notes

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.

3. The linking evidence to recommendations sections drafted at GDG were reviewed (carbohydrate counting; technology for self-monitoring of blood glucose; needle length, injection site and rotation). GDG comments will be incorporated into the next version.

4. The GDG reviewed the clinical and cost effectiveness evidence for insulin induced neuropathy. Draft recommendations were made.

5. The GDG discussed the gastroparesis evidence review and agreed that type 2 population should be included. The evidence review will be updated and presented at a later GDG meeting.

6. The GDG reviewed the evidence and recommendations on blood glucose targets for children and young people. The GDG re-debated type 1 diabetes recommendations on blood glucose targets and will feed back to the diabetes in children and young people guideline developers.

7. The GDG were informed about the forthcoming consultations for the lipids modification and chronic kidney disease guidelines. The GDG will formulate responses at GDG14.

8. The GDG reviewed the clinical and cost effectiveness evidence on erectile dysfunction and draft recommendations were made.

9. The GDG reviewed the clinical and cost effectiveness evidence on inpatient intravenous insulin regimens and dose adjustment devices and draft recommendations were made.

10. An update was given on costs for the health economics models.

11. Protocols for identification of hypoglycaemia unawareness, strategies for managing hypoglycaemia unawareness, thyroid disease monitoring and pancreas / pancreatic islet cell transplantation were finalised.

12. Future meeting dates were confirmed.

Date, time and venue of the next meeting

4. Tuesday 4th March 2014, 1000 1600 at the National Clinical Guideline Centre, 180 Great Portland Street, London W1W 4QZ